Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2012
08/30/2012WO2012116066A1 Controlled release hydrogel formulation
08/30/2012WO2012116061A1 Combination therapy of hsp90 inhibitory compounds with radiotherapy
08/30/2012WO2012116050A2 Phosphorus containing compounds as protein kinase inhibitors
08/30/2012WO2012116048A1 Single step heparosan n-deacetylation and depolymerization for making bioengineered heparin
08/30/2012WO2012116010A2 Antibiotic tolerance inhibitors
08/30/2012WO2012115952A1 Evaluating heparin preparations
08/30/2012WO2012115946A1 Treating human male copd patients with oral bedoradrine
08/30/2012WO2012115945A1 Viral inhibitors
08/30/2012WO2012115695A1 Bis-fatty acid conjugates and their uses
08/30/2012WO2012115659A1 Compositions and methods for controlled delivery of compounds
08/30/2012WO2012115655A1 Formulations of canfosfamide and their preparation
08/30/2012WO2012115608A2 Polyamine inhibitors for the treatment and prevention of parkinson's disease
08/30/2012WO2012115575A1 Derivatives for inducing osteogenic differentiation
08/30/2012WO2012115538A1 Clathrate complex of cyclodextrin or arabinogalactan with 9-phenyl-sym-octahydroselenoxanthene
08/30/2012WO2012115480A2 Diaminopyrimidine derivatives and processes for the preparation thereof
08/30/2012WO2012115479A2 Diaminopyrimidine derivatives and processes for the preparation thereof
08/30/2012WO2012115478A2 Diaminopyrimidine derivatives and processes for the preparation thereof
08/30/2012WO2012115446A2 Compound based on 5-(substituted alkyl-aminomethyl) isoxazole acting as a t-type calcium channel antagonist
08/30/2012WO2012115402A2 Crystalline form of docetaxel and process for preparation thereof
08/30/2012WO2012115306A1 Composition including vitamin c for protecting fetal nerve cells, and functional health food including same
08/30/2012WO2012115286A1 Alpha helix mimetics and methods relating thereto
08/30/2012WO2012115256A1 C-4" position substituted macrolide derivative
08/30/2012WO2012115249A1 Crystal of spiroketal derivative
08/30/2012WO2012115247A1 Stratum corneum peeling accelerator
08/30/2012WO2012115226A1 Therapeutic agent for cancer
08/30/2012WO2012115209A1 Soluble epoxide hydrolase inhibitor
08/30/2012WO2012115182A1 Therapeutic agent for corneal sensory nerve damage containing semaphorin inhibitor as active ingredient
08/30/2012WO2012115177A1 N-[(biaryloxy)alkylcarbonyl]sulfonamide derivative
08/30/2012WO2012115176A1 3-(biaryloxy)propionic acid derivative
08/30/2012WO2012115097A1 Glycine transport inhibitor
08/30/2012WO2012115066A1 Glycine transport inhibitor
08/30/2012WO2012115026A1 Tomatoside a-containing composition
08/30/2012WO2012114926A1 Thioamide compound, method for producing thioamide compound, method for producing [(4r,6r)-6-aminoethyl-1,3-dioxane-4-yl]acetate derivative, and method for producing atorvastatin
08/30/2012WO2012114355A1 Novel process for preparation of linezolid and its novel intermediates
08/30/2012WO2012114352A2 Pharmaceutical compositions of maraviroc and process for the preparation thereof
08/30/2012WO2012114348A1 Novel compounds as histamine h3 receptor ligands
08/30/2012WO2012114325A1 Polymorphs of asenapine maleate
08/30/2012WO2012114317A1 Novel rebamipide complexes and cocrystals
08/30/2012WO2012114285A1 Heteroaryl derivatives as alpha7 nachr modulators
08/30/2012WO2012114268A1 Benzamide derivatives as p2x7 receptor antagonists
08/30/2012WO2012114252A1 Novel indole and pyrrolopyridine amides
08/30/2012WO2012114223A1 A method of treating liver fibrosis
08/30/2012WO2012114222A1 IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
08/30/2012WO2012114204A2 Methods of treating mitochondrial dysfunction
08/30/2012WO2012114201A1 Nanocapsulation of essential oils for preventing or curing infectious diseases alone or with an antibiotic
08/30/2012WO2012114196A1 Pharmaceutical formulation comprising compounds of the jasmonate family
08/30/2012WO2012113967A1 Gsk-3 inhibitors that can be used in neurodegenerative and inflammatory diseases, cancer, diabetes and in regenerative processes
08/30/2012WO2012113963A1 Use of p53 inhibitors for reducing food intake and lowering body weight
08/30/2012WO2012113920A1 Arylsulfone derivatives with activity against human betaherpesviruses
08/30/2012WO2012113897A1 Antitumoral combination comprising cabazitaxel and cisplatin
08/30/2012WO2012113894A1 Pharmaceutical combination of betahistine and trimetazidine
08/30/2012WO2012113891A1 Use of polyaminoisoprenyl derivatives in antibiotic or antiseptic treatment
08/30/2012WO2012113850A2 (PYRIDIN-4-YL)BENZYLAMIDES AS ALLOSTERIC MODULATORS OF ALPHA 7 nAChR
08/30/2012WO2012113835A1 C-glucosidic ellagitannin compounds for use for altering the supramolecular arrangement of actin and for the treatment of osteoporosis, cancer, bacterial infection and viral infection
08/30/2012WO2012113819A1 Molecular biomarkers for predicting response to antitumor treatment in lung cancer
08/30/2012WO2012113774A1 Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors
08/30/2012WO2012113677A1 Prebiotic carbohydrate compositions
08/30/2012WO2012113594A1 Use of nifuratel to treat infections caused by clostridium species
08/30/2012WO2012113572A1 Ketogenic diet composition for the treatment of chemo therapy and/or radiation therapy patients
08/30/2012WO2012113564A1 Stabilized granules containing glyceryl trinitrate
08/30/2012WO2012113563A1 Packaging of solid pharmaceutical preparations containing the active substance glyceryl trinitrate
08/30/2012WO2012113503A1 Composition to increase joint and/or postural stability
08/30/2012WO2012113415A1 Ketogenic diet composition for the treatment of chemo therapy and/or radiation therapy patients
08/30/2012WO2012113343A1 Use of il-17 inhibitor in preparation of drug for treating and/or preventing lung injury
08/30/2012WO2012113179A1 Sustained release pharmaceutical composition of zaltoprofen and preparation method thereof
08/30/2012WO2012113116A1 Emulsion containing hydrophilic biological macromolecule, preparation method and application thereof
08/30/2012WO2012113103A1 Asymmetric ureas and medical uses thereof
08/30/2012WO2012113079A1 Cystamine analogues for the treatment of parkinson's disease
08/30/2012WO2012113072A1 A method for the selection of dna ligands for a molecular target
08/30/2012WO2012113067A1 Oligonucleotide inhibitors with chimeric backbone and 2-amino-2'-deoxyadenosine
08/30/2012WO2012094081A3 System and method for identifying and applying peripheral treatment mechanisms for disease
08/30/2012WO2012092157A3 Nutritional formulations including human milk oligosaccharides and long chain polyunsaturated polyunsaturated fatty acids and uses thereof
08/30/2012WO2012085657A3 Tamper resistant solid oral dosage forms
08/30/2012WO2012080184A3 Liquid pharmaceutical compositions which can be administered orally and contain 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophene carboxamide
08/30/2012WO2012073214A3 Heptose derivatives for use in the treatment of bacterial infections
08/30/2012WO2012062901A3 Chromene derivatives and their analoga as wnt pathway antagonists
08/30/2012WO2012058073A3 Methods and compositions to protect aquatic invertebrates from disease
08/30/2012WO2012057492A3 Rapamycin formulation using recombinant high-density lipoprotein including apolipoprotein a-i and a mutant thereof
08/30/2012WO2012054862A9 Agents, compositions, and methods for treating pruritis and related skin conditions
08/30/2012WO2012054521A8 Antimicrobial polyether and polyol compounds
08/30/2012WO2012053012A3 Topical pharmaceutical compositions comprising tfflocolchicoside
08/30/2012WO2012046250A3 Polymorphic forms of o-desmethyl-venlafaxine succinate field of the invention
08/30/2012WO2012032151A3 Hybrid cooperative complexes of hyaluronic acid
08/30/2012WO2012016707A3 Oral dosage form for the modified release of dimebolin
08/30/2012WO2012015999A3 Process for the preparation of imatinib mesylate
08/30/2012WO2012013782A3 Compositions for controlling heartworm infestation
08/30/2012WO2012001156A3 Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts
08/30/2012WO2011121019A3 Method for producing a drug delivery system on the basis of polyelectrolyte complexes
08/30/2012WO2011058572A3 Solid dapoxetine
08/30/2012US20120222142 Gut flora-derived extracellular vesicles, and method for searching for a disease model, vaccine, and candidate drug and for diagnosis using the same
08/30/2012US20120222141 Islet1 (isl1) and hearing loss
08/30/2012US20120220961 Ophthalmic Solutions
08/30/2012US20120220922 Photolabile compounds
08/30/2012US20120220759 Synthetic heparin disaccharides
08/30/2012US20120220667 Use of methylsulfonylmethane (msm) to inhibit microbial activity
08/30/2012US20120220666 Composition to enhance the bioavailability of curcumin
08/30/2012US20120220665 Inhibiting Neurotransmitter Reuptake
08/30/2012US20120220664 Use of metformin in cancer treatment and prevention
08/30/2012US20120220663 Solid forms of aliskiren hemifumarate and processes for preparation thereof
08/30/2012US20120220662 Phytoceutical compositions for pets
1 ... 1063 1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 ... 7860